Consolidated Condensed Balance Sheets - USD ($) $ in Millions	Sep. 30, 2021	Dec. 31, 2020
Current Assets
Cash and cash equivalents (Note 6)	$ 3,788.2	$ 3,657.1
Short-term investments (Note 6)	37.1	24.2
Accounts receivable, net of allowances of $24.1 (2021) and $25.9 (2020)	5,914.3	5,875.3
Other receivables	1,110.7	1,053.7
Inventories	3,907.4	3,980.3
Prepaid expenses and other	3,050.6	2,871.5
Total current assets	17,808.3	17,462.1
Investments (Note 6)	3,350.5	2,966.8
Goodwill	3,884.1	3,766.5
Other intangibles, net	7,887.7	7,450.0
Deferred tax assets	2,625.6	2,830.4
Property and equipment, net of accumulated depreciation of $9,962.8 (2021) and $9,570.7 (2020)	8,920.4	8,681.9
Other noncurrent assets	3,710.4	3,475.4
Total assets	48,187.0	46,633.1
Current Liabilities
Short-term borrowings and current maturities of long-term debt	1,563.0	8.7
Accounts payable	1,566.8	1,606.7
Employee compensation	836.6	997.2
Sales rebates and discounts	7,185.6	5,853.0
Dividends payable	0.0	770.6
Income taxes payable	203.5	495.1
Other current liabilities	2,326.5	2,750.3
Total current liabilities	13,682.0	12,481.6
Other Liabilities
Long-term debt	15,522.4	16,586.6
Accrued retirement benefits (Note 8)	3,878.8	4,094.5
Long-term income taxes payable	3,768.5	3,837.8
Deferred tax liabilities	1,632.5	2,099.9
Other noncurrent liabilities	1,748.7	1,707.5
Total other liabilities	26,550.9	28,326.3
Commitments and Contingencies (Note 9)
Eli Lilly and Company Shareholders’ Equity
Common stock	598.2	598.2
Additional paid-in capital	6,758.0	6,778.5
Retained earnings	9,639.4	7,830.2
Employee benefit trust	(3,013.2)	(3,013.2)
Accumulated other comprehensive loss (Note 10)	(6,172.7)	(6,496.4)
Cost of common stock in treasury	(52.7)	(55.7)
Total Eli Lilly and Company shareholders’ equity	7,757.0	5,641.6
Noncontrolling interests	197.1	183.6
Total equity	7,954.1	5,825.2
Total liabilities and equity	$ 48,187.0	$ 46,633.1